TMCnet News
Study Reveals Gender Differences in Migraine TreatmentDUBLIN, June 10, 2016 /PRNewswire/-- Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that new data presented at the American Headache Society (AHS) annual scientific meeting reveals differences between the way men and women react to migraines, suggesting underlying disparities in headache characteristics and progression.i The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study longitudinally explored the causes and burden of Chronic Migraine and Episodic Migraine, both part of the spectrum of migraine disorders but distinct clinical entities. Chronic Migraine is a neurological condition characterized by 15 or more headache days per month, with headaches lasting four hours a day or longer, and at least eight of those headache days being associated with migraine, while Episodic Migraine is defined as less than 15 headache days per month.ii Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO Migraine is one of the most common neurologic disorders in both men and women, but its misperception as a "women's disease" may contribute to migraine stigma in men.i The web-based-study of 16,789 men and women with migraine assessed differences in sociodemographics, headache symptomology, disability, diagnosis, and treatment.i "Despite gender differences in attack features, these conditions are disabling in men. Chronic Migraine, in particular, has been found to impact daily life inside and outside the home," explained Dr. Richard B. Lipton, an Edwin S. Lowe Professor and Vice Chair of Neurology, Professor of Epidemiology and Population Health and Professor of Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine.iii "Men need to know that there are treatments available and it's okay to ask for help." Data indicated differences in the way men and women receive diagnoses, interact with healthcare providers and manage the conditions. According to Dr. Lipton, "As we work to better understand whether men have a different migraine pathophysiology than women, it's important to encourage everyone – men and women – who is experiencing symptoms to seek an accurate diagnosis." Funding for the Chronic Migraine Epidemiology and Outcomes (CaMEO) study was provided by Allergan plc. "Allergan is dedicated to advancing research to help the estimated 36 million Americans wh are living with the debilitating effects of migraine,[iv]" said David Nicholson, Chief R&D Officer at Allergan. "The more information patients have, the better equipped they will be to make critical decisions about their own health, including when to seek help and what treatment options are available." For more information about Chronic Migraine, including a screening tool, visit MyChronicMigraine.com. About Allergan Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally. With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives. For more information, visit Allergan's website at www.allergan.com. Forward-Looking Statement For more information, visit Allergan's website at www.allergan.com. iScher I. Ann, PhD, et al. Epidemiology of Migraine in Men: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. CONTACTS: Media: Lisa Kim To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/study-reveals-gender-differences-in-migraine-treatment-300282890.html SOURCE Allergan plc |